accountTauRX Therapeutics had just released what appeared to be spectacular data from Phase II clinical trials for their Alzheimer's drug, called rember. 'Researchers say that rember slowed cognitive decline in 81 percent of the patients taking the drug,' the...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Desperate for a Cure
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account